Status:

COMPLETED

Effect of Memantine on Cognitive Impairment in Patients With Epilepsy

Lead Sponsor:

Assiut University

Conditions:

Epilepsy

Eligibility:

All Genders

18-55 years

Phase:

PHASE1

Brief Summary

Evaluate the efficacy of memantine on improving the cognitive impairment in patient with epilepsy

Detailed Description

Epilepsy is a complex disorder, which involves much more than seizures, encompassing a range of associated comorbid health conditions that can have significant health and quality-of-life implications....

Eligibility Criteria

Inclusion

  • Patients with idiopathic epilepsy.
  • Normal brain imaging (CT brain).
  • Patients on anti epileptic drugs more than 6 months.
  • No more than two fits per month.
  • Score of Mini mental state examination (10-24), mild and moderate cognitive impairment.
  • No other medical disorders.

Exclusion

  • Progressive neurological diseases.
  • Abnormal brain imaging (CT brain).
  • More than two fits per month.
  • Patients with severe cognitive impairment, score of MMSE less than10.
  • Patients with severe medical disorders

Key Trial Info

Start Date :

October 1 2018

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 15 2020

Estimated Enrollment :

100 Patients enrolled

Trial Details

Trial ID

NCT04417543

Start Date

October 1 2018

End Date

January 15 2020

Last Update

June 4 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Salma Mohmed Fahmy

Asyut, Egypt